NCLT Admits Insolvency Plea Against Shilpa Medicare Subsidiary FTF Pharma
NCLT admitted an insolvency application against FTF Pharma, a wholly-owned subsidiary of Shilpa Medicare. The application was filed by Immacule Lifesciences for an alleged operational debt of ₹2.18 crore. The NCLT ordered the commencement of Corporate Insolvency Resolution Process (CIRP) against FTF Pharma.
The insolvency of a subsidiary can impact the parent company's financials and operations, although the extent is not yet quantifiable. The company is evaluating the situation.
The NCLT admitting an insolvency resolution process against a subsidiary is a negative development for the company, indicating financial distress at the subsidiary level.
Shilpa Medicare Limited has announced that the National Company Law Tribunal (NCLT), Ahmedabad Bench, has admitted an application filed under Section 9 of the Insolvency and Bankruptcy Code, 2016. The application was filed by Immacule Lifesciences Private Limited against FTF Pharma Private Limited, a wholly-owned subsidiary of Shilpa Medicare.
The NCLT, in its order pronounced on September 9, 2026, has ordered the commencement of the Corporate Insolvency Resolution Process (CIRP) against FTF Pharma. The proceedings were initiated due to an alleged operational debt of ₹2,18,03,319 claimed by Immacule Lifesciences. The NCLT found the outstanding debt to be proven and noted the absence of a valid pre-existing dispute.
The order also includes the commencement of a moratorium under Section 14 of the IBC and appoints Mr. Sunil Kumar Kedia as the Interim Resolution Professional (IRP). Shilpa Medicare Limited is currently in discussions with its legal advisors to evaluate the legal position and determine the future course of action. The company stated that the impact on its financial and operational activities is not yet ascertainable or quantifiable but will provide further updates as required.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.